Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (8040) 8040
Publication (1549) 1549
Book Review (96) 96
Book Chapter (52) 52
Newsletter (46) 46
Book / eBook (33) 33
Conference Proceeding (27) 27
Dissertation (12) 12
Reference (5) 5
Data Set (3) 3
Magazine Article (3) 3
Government Document (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
animals (5727) 5727
index medicus (3653) 3653
male (3501) 3501
pharmacology & pharmacy (3031) 3031
rats (3003) 3003
neurosciences (2459) 2459
humans (2325) 2325
mice (2239) 2239
pyrazoles - pharmacology (2233) 2233
piperidines - pharmacology (2125) 2125
endocannabinoids (2012) 2012
cannabinoids (1670) 1670
receptor, cannabinoid, cb1 - antagonists & inhibitors (1572) 1572
anandamide (1430) 1430
receptor, cannabinoid, cb1 - metabolism (1380) 1380
dose-response relationship, drug (1358) 1358
cannabinoids - pharmacology (1220) 1220
rats, sprague-dawley (1170) 1170
endocannabinoid system (1112) 1112
cannabinoid (1105) 1105
arachidonic acids - pharmacology (1097) 1097
brain (1077) 1077
cannabinoid receptor (999) 999
rats, wistar (956) 956
morpholines - pharmacology (914) 914
female (873) 873
naphthalenes - pharmacology (861) 861
cannabinoid receptors (857) 857
rimonabant (849) 849
receptors, cannabinoid (840) 840
lipids (825) 825
receptor, cannabinoid, cb1 - agonists (812) 812
article (748) 748
psychiatry (737) 737
pharmacology (727) 727
dronabinol - pharmacology (722) 722
activation (712) 712
mice, inbred c57bl (705) 705
biochemistry & molecular biology (638) 638
receptors (635) 635
disease models, animal (628) 628
cb1 receptor (621) 621
receptor, cannabinoid, cb2 - metabolism (606) 606
ligands (605) 605
inhibition (603) 603
rat (594) 594
acid amide hydrolase (584) 584
nervous system (580) 580
rat-brain (576) 576
receptor (560) 560
neurons (535) 535
receptor, cannabinoid, cb1 - physiology (529) 529
rodents (527) 527
arachidonic acids - metabolism (524) 524
research (521) 521
mice, knockout (518) 518
expression (516) 516
in vitro techniques (515) 515
cb1 (513) 513
physiological aspects (510) 510
cannabinoid receptor modulators - metabolism (506) 506
antagonist (504) 504
polyunsaturated alkamides (504) 504
cannabinoid cb1 receptors (502) 502
analysis (500) 500
cb1 receptors (498) 498
pain (477) 477
enzyme inhibitors - pharmacology (474) 474
amidohydrolases - antagonists & inhibitors (462) 462
benzoxazines (461) 461
chemistry, medicinal (452) 452
receptors, drug - antagonists & inhibitors (444) 444
neurons - drug effects (441) 441
behavior, animal - drug effects (437) 437
marijuana (436) 436
receptor, cannabinoid, cb1 - genetics (435) 435
endogenous cannabinoids (432) 432
receptor, cannabinoid, cb2 - agonists (432) 432
cells, cultured (430) 430
obesity (430) 430
benzoxazines - pharmacology (426) 426
inflammation (421) 421
receptor, cannabinoid, cb2 - antagonists & inhibitors (421) 421
brain - metabolism (418) 418
time factors (407) 407
delta-tetrahydrocannabinol (402) 402
signal transduction - drug effects (397) 397
endocannabinoids - metabolism (391) 391
motor activity - drug effects (390) 390
in-vivo (389) 389
brain - drug effects (385) 385
endocannabinoid (385) 385
physiology (370) 370
cannabinoids - metabolism (363) 363
cannabinoid receptor modulators - pharmacology (361) 361
cannabinoid receptor antagonists - pharmacology (360) 360
receptors, drug - metabolism (358) 358
receptors, cannabinoid - metabolism (355) 355
analgesics - pharmacology (350) 350
health aspects (346) 346
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (16) 16
Collection Dvlpm't (Acquisitions) - Vendor file (5) 5
Robarts - Stacks (3) 3
UofT at Mississauga - Stacks (3) 3
UofT at Scarborough - Stacks (3) 3
Collection Dvlpm't (Acquisitions) - Closed Orders (2) 2
Criminology - Stacks (1) 1
Online Resources - Online (1) 1
St. Michael's College (John M. Kelly) - 2nd Floor (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (8114) 8114
Japanese (13) 13
French (12) 12
German (10) 10
Russian (9) 9
Chinese (6) 6
Spanish (4) 4
Portuguese (3) 3
Hungarian (2) 2
Italian (2) 2
Norwegian (1) 1
Polish (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Modulating the endocannabinoid system in human health and disease – successes and failures
by Pacher, Pál and Kunos, George
FEBS Journal, ISSN 1742-464X, 05/2013, Volume 280, Issue 9, pp. 1918 - 1943
The discovery of the endocannabinoid system, comprising the G‐protein coupled cannabinoid 1 and 2 receptors ( CB 1/2 ), their endogenous lipid ligands or... 
disease | therapeutic potential | pharmacology | cannabinoids | clinical trials | endocannabinoid system | human | HUMAN MONOCYTE MIGRATION | BIOCHEMISTRY & MOLECULAR BIOLOGY | FOS PROTEIN EXPRESSION | AMYOTROPHIC-LATERAL-SCLEROSIS | HEPATIC ISCHEMIA/REPERFUSION INJURY | CANNABINOID CB2 RECEPTORS | ISCHEMIA-REPERFUSION INJURY | ACID AMIDE HYDROLASE | ACUTE MYOCARDIAL-INFARCTION | CEREBRAL ISCHEMIC/REPERFUSION INJURY | CORONARY-ARTERY-DISEASE | Health | Cardiovascular Diseases - drug therapy | Humans | Pain Management | Receptors, Cannabinoid - physiology | Cannabinoid Receptor Antagonists - adverse effects | Clinical Trials as Topic | Cannabinoid Receptor Agonists - pharmacology | Cannabinoid Receptor Antagonists - therapeutic use | Cannabinoids - adverse effects | Cannabinoids - pharmacology | Cannabinoids - therapeutic use | Endocannabinoids - physiology | Animals | Signal Transduction - drug effects | Inflammation - drug therapy | Cannabinoid Receptor Agonists - adverse effects | Cannabinoid Receptor Agonists - therapeutic use | Cannabinoid Receptor Antagonists - pharmacology | Cardiovascular Diseases - chemically induced | Chemotherapy | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Pharmacology of Indole and Indazole Synthetic Cannabinoid Designer Drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA, and 5F-ADBICA
by Banister, Samuel D and Moir, Michael and Stuart, Jordyn and Kevin, Richard C and Wood, Katie E and Longworth, Mitchell and Wilkinson, Shane M and Beinat, Corinne and Buchanan, Alexandra S and Glass, Michelle and Connor, Mark and McGregor, Iain S and Kassiou, Michael
ACS Chemical Neuroscience, ISSN 1948-7193, 07/2015, Volume 6, Issue 9, pp. 1546 - 1559
Synthetic cannabinoid (SC) designer drugs based on indole and indazole scaffolds and featuring L-valinamide or L-tert-leucinamide side chains are encountered... 
FUBINACA | JWH-018 | Cannabinoid | PINACA | THC | SR 144528 | SELECTIVE ANTAGONIST | CHEMISTRY, MEDICINAL | BIOCHEMISTRY & MOLECULAR BIOLOGY | 1ST POTENT | RATS | ILLEGAL PRODUCTS | ALPHA-PVT | NEUROSCIENCES | RECEPTOR ANTAGONIST | INTERNATIONAL UNION | DERIVATIVES | SR141716A | Rats, Wistar | Receptor, Cannabinoid, CB2 - agonists | Body Temperature - drug effects | Indazoles - chemical synthesis | Humans | Indoles - chemical synthesis | Male | Receptor, Cannabinoid, CB2 - antagonists & inhibitors | Cannabinoid Receptor Agonists - chemistry | Cannabinoid Receptor Agonists - pharmacology | Receptor, Cannabinoid, CB2 - genetics | Dose-Response Relationship, Drug | Heart Rate - drug effects | Receptor, Cannabinoid, CB1 - agonists | Cannabinoid Receptor Antagonists - pharmacology | Indoles - pharmacology | Molecular Structure | Drug Evaluation, Preclinical | Membrane Potentials - drug effects | Designer Drugs - pharmacology | Indazoles - chemistry | Cannabinoid Receptor Agonists - chemical synthesis | Designer Drugs - chemical synthesis | Indazoles - pharmacology | Designer Drugs - chemistry | Receptor, Cannabinoid, CB1 - metabolism | Receptor, Cannabinoid, CB2 - metabolism | Animals | Receptor, Cannabinoid, CB1 - genetics | Cell Line, Tumor | Mice | Receptor, Cannabinoid, CB1 - antagonists & inhibitors | Indoles - chemistry | Cohort Studies
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease
by Armentero, MT and Pinna, A and Ferre, S and Lanciego, JL and Muller, CE and Franco, R
PHARMACOLOGY & THERAPEUTICS, ISSN 0163-7258, 12/2011, Volume 132, Issue 3, pp. 280 - 299
Several selective antagonists for adenosine A(2A) receptors (A(2A)R) are currently under evaluation in clinical trials (phases I to III) to treat Parkinson's... 
Neuroprotection | Basal ganglia | BONE-MARROW-CELLS | BLOOD-BRAIN-BARRIER | Presynaptic heteromer | TREMULOUS JAW MOVEMENTS | BASAL GANGLIA CIRCUITRY | Postsynaptic heteromer | POSITRON-EMISSION-TOMOGRAPHY | MPTP-TREATED MONKEYS | CANNABINOID CB1 RECEPTORS | MONOAMINE-OXIDASE-B | Heteromer-selective antagonist | PHARMACOLOGY & PHARMACY | CENTRAL-NERVOUS-SYSTEM | Receptor heteromer | C-FOS EXPRESSION | Adenosine A2 Receptor Antagonists - pharmacology | Animals | Adenosine A2 Receptor Antagonists - therapeutic use | Humans | Basal Ganglia - metabolism | Clinical Trials as Topic | Parkinson Disease - drug therapy | Parkinson Disease - metabolism | Receptor, Adenosine A2A - metabolism | Drug Evaluation, Preclinical | Receptors, Dopamine D2 - metabolism | Basal Ganglia - drug effects | Adenosine | Cell receptors | Malaltia de Parkinson | Parkinson's disease | Adenosina | Receptors cel·lulars
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text CB1 and CB2 cannabinoid receptor agonists induce peripheral antinociception by activation of the endogenous noradrenergic system
by Romero, Thiago R. L and Resende, Livia C and Guzzo, Luciana S and Duarte, Igor D. G
Anesthesia and Analgesia, ISSN 0003-2999, 02/2013, Volume 116, Issue 2, pp. 463 - 472
BACKGROUND: Cannabinoid agonists induce norepinephrine release in central, spinal, and peripheral sites. Previous studies suggest an interaction between the... 
NEUROPATHIC PAIN | INFLAMED TISSUE | RAT FRONTAL-CORTEX | ALPHA-2-ADRENOCEPTOR SUBTYPES | FATTY-ACID AMIDE | SPINAL-CORD | ANESTHESIOLOGY | NONCATECHOLIC PHENYLETHYLAMINE DERIVATIVES | NOREPINEPHRINE RELEASE | FORMALIN TEST | DORSAL-ROOT GANGLION | Analgesics - pharmacology | Ethanolamines - pharmacology | Endocannabinoids - pharmacology | Rats, Wistar | Receptor, Cannabinoid, CB2 - agonists | Norepinephrine - physiology | Sympathetic Nervous System - drug effects | Dinoprostone | Male | Cannabinoid Receptor Agonists - pharmacology | Peripheral Nerves - drug effects | Yohimbine - pharmacology | Adrenergic beta-Antagonists - pharmacology | Propranolol - pharmacology | Receptor, Cannabinoid, CB1 - agonists | Adrenergic alpha-1 Receptor Antagonists - pharmacology | Prazosin - pharmacology | Palmitic Acids - pharmacology | Palmitic Acids - antagonists & inhibitors | Morpholines - pharmacology | Rats | Pain Measurement - drug effects | Ethanolamines - antagonists & inhibitors | Polyunsaturated Alkamides - antagonists & inhibitors | Adrenergic alpha-2 Receptor Antagonists - pharmacology | Arachidonic Acids - pharmacology | Animals | Arachidonic Acids - antagonists & inhibitors | Polyunsaturated Alkamides - pharmacology | Adrenergic Uptake Inhibitors - pharmacology | Endocannabinoids - antagonists & inhibitors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Chronic Cannabinoid Receptor 2 Activation Reverses Paclitaxel Neuropathy Without Tolerance or Cannabinoid Receptor 1–Dependent Withdrawal
by Deng, Liting and Guindon, Josée and Cornett, Benjamin L and Makriyannis, Alexandros and Mackie, Ken and Hohmann, Andrea G
Biological Psychiatry, ISSN 0006-3223, 2015, Volume 77, Issue 5, pp. 475 - 487
Abstract Background Mixed cannabinoid receptor 1 and 2 (CB1 and CB2 ) agonists such as Δ9 -tetrahydrocannabinol (Δ9 -THC) can produce tolerance, physical... 
Psychiatry | Tolerance | CB2 | Precipitated withdrawal | Chemotherapy-induced neuropathic pain | Knockout mouse | Side effect | DORSAL-HORN NEURONS | MECHANICAL ALLODYNIA | PSYCHIATRY | VENTRAL ROOT TRANSECTION | CB2 RECEPTOR | INDUCED PERIPHERAL NEUROPATHY | SPINAL-CORD | NECROSIS-FACTOR-ALPHA | NERVE INJURY | NEUROSCIENCES | ACID AMIDE HYDROLASE | PRIMARY SENSORY NEURONS | Hyperalgesia - chemically induced | Tumor Necrosis Factor-alpha - metabolism | Spinal Cord - drug effects | Receptor, Cannabinoid, CB2 - agonists | Male | Cannabinoid Receptor Agonists - pharmacology | RNA, Messenger - metabolism | Receptor, Cannabinoid, CB2 - genetics | Paclitaxel - toxicity | Receptor, Cannabinoid, CB1 - agonists | Cannabinoid Receptor Antagonists - pharmacology | Female | Indoles - pharmacology | Chemokine CCL2 - metabolism | Chromones - pharmacology | Dronabinol - pharmacology | Disease Models, Animal | Mice, Inbred C57BL | Random Allocation | Hyperalgesia - physiopathology | Mice, Knockout | Antineoplastic Agents, Phytogenic - toxicity | Receptor, Cannabinoid, CB1 - metabolism | Receptor, Cannabinoid, CB2 - metabolism | Animals | Receptor, Cannabinoid, CB1 - genetics | Hyperalgesia - drug therapy | Spinal Cord - physiopathology | Receptor, Cannabinoid, CB1 - antagonists & inhibitors | Cannabinoids | Neurosciences | Paclitaxel
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. A selective antagonist reveals a potential role of G protein-coupled receptor 55 in platelet and endothelial cell function
by Kargl, Julia and Brown, Andrew J and Andersen, Liisa and Dorn, Georg and Schicho, Rudolf and Waldhoer, Maria and Heinemann, Akos
Journal of Pharmacology and Experimental Therapeutics, ISSN 0022-3565, 07/2013, Volume 346, Issue 1, pp. 54 - 66
The G protein-coupled receptor 55 (GPR55) is a lysophosphatidylinositol (LPI) receptor that is also responsive to certain cannabinoids. Although GPR55 has been... 
IN-VITRO | ACTIVATION | CANNABINOID RECEPTOR | ASSAY | L-ALPHA-LYSOPHOSPHATIDYLINOSITOL | LIGANDS | GPR55 | PHARMACOLOGY & PHARMACY | PROLIFERATION | IDENTIFICATION | CANCER | Azabicyclo Compounds - pharmacology | Endothelium, Vascular - cytology | Lysophospholipids - metabolism | Receptors, G-Protein-Coupled - metabolism | Humans | NFATC Transcription Factors - agonists | Endothelium, Vascular - drug effects | NF-kappa B - metabolism | Protein Transport - drug effects | Sulfones - antagonists & inhibitors | RNA, Messenger - metabolism | Receptor, Cannabinoid, CB2 - genetics | Sulfones - pharmacology | Recombinant Fusion Proteins - metabolism | HEK293 Cells | Platelet Aggregation - ethics | Cannabinoid Receptor Antagonists - pharmacology | Piperazines - antagonists & inhibitors | Platelet Aggregation - drug effects | Blood Platelets - drug effects | Wound Healing - drug effects | Gene Expression | NF-kappa B - antagonists & inhibitors | Lysophospholipids - antagonists & inhibitors | NFATC Transcription Factors - metabolism | Cells, Cultured | Piperazines - pharmacology | Receptor, Cannabinoid, CB1 - metabolism | Receptor, Cannabinoid, CB2 - metabolism | Receptor, Cannabinoid, CB1 - genetics | Blood Platelets - metabolism | Calcium Signaling - drug effects | Endothelium, Vascular - metabolism | Receptors, G-Protein-Coupled - antagonists & inhibitors | Benzoates - pharmacology | Ligands | Receptors, G-Protein-Coupled - genetics | NFATC Transcription Factors - antagonists & inhibitors | Receptors, G-Protein-Coupled - chemistry
Journal Article
Details down arrow
7. Full Text Antiepileptic action of N-palmitoylethanolamine through CB1 and PPAR-α receptor activation in a genetic model of absence epilepsy
by Citraro, Rita and Russo, Roberto and Russo, Emilio and Scicchitano, Francesca and van Rijn, Clementina M and Cosco, Donato and Avagliano, Carmen and D'Agostino, Giuseppe and Petrosino, Stefania and Guida, Francesca and Gatta, Luisa and van Luijtelaar, Gilles and Maione, Sabatino and Di Marzo, Vincenzo and Calignano, Antonio and De Sarro, Giovambattista
Neuropharmacology, ISSN 0028-3908, 06/2013, Volume 69, pp. 115 - 126
-palmitoylethanolamine (PEA), an endogenous fatty acid ethanolamide, plays a key role in the regulation of the inflammatory response and pain through, among... 
Absence seizures | GW6471 | SWDs | SR141716 | Endocannabinoids | Anandamide | DEPRESSIVE-LIKE BEHAVIOR | ACID | NUCLEAR | PALMITOYL-ETHANOLAMINE | NEUROSCIENCES | NEUROPROTECTION | ANTICONVULSANT ACTIVITY | ANIMAL-MODELS | PHARMACOLOGY & PHARMACY | WAG/RIJ RATS | Tyrosine - pharmacology | Ethanolamines - pharmacology | PPAR alpha - drug effects | Endocannabinoids - pharmacology | Rats, Wistar | Injections, Intraventricular | Male | Tyrosine - analogs & derivatives | Dose-Response Relationship, Drug | Piperidines - pharmacology | Cannabinoid Receptor Antagonists - pharmacology | Palmitic Acids - pharmacology | Pyrazoles - pharmacology | PPAR alpha - antagonists & inhibitors | Epilepsy, Absence - genetics | Rats | Calcium Channel Blockers - pharmacology | Arachidonic Acids - pharmacology | Anticonvulsants | Glycerides - pharmacology | Animals | Electroencephalography - drug effects | Lipid Metabolism - drug effects | Polyunsaturated Alkamides - pharmacology | Receptor, Cannabinoid, CB1 - drug effects | Epilepsy, Absence - drug therapy | Oxazoles - pharmacology | Receptor, Cannabinoid, CB1 - antagonists & inhibitors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text CB1 and CB2 cannabinoid receptor antagonists prevent minocycline-induced neuroprotection following traumatic brain injury in mice
by Lopez-Rodriguez, Ana Belen and Siopi, Eleni and Finn, David P and Marchand-Leroux, Catherine and Garcia-Segura, Luis M and Jafarian-Tehrani, Mehrnaz and Viveros, Maria-Paz
Cerebral Cortex, ISSN 1047-3211, 01/2015, Volume 25, Issue 1, pp. 35 - 45
Traumatic brain injury (TBI) and its consequences represent one of the leading causes of death in young adults. This lesion mediates glial activation and the... 
Minocycline | Neuroprotection | Traumatic brain injury | Diffuse axonal injury | Microglial activation | Cannabinoid system | CELLS | diffuse axonal injury | ALZHEIMERS-DISEASE | FOCAL CEREBRAL-ISCHEMIA | traumatic brain injury | KAPPA-B | NEUROSCIENCES | CLOSED-HEAD INJURY | PROTECTS NEURONS | minocycline | neuroprotection | EDEMA | IN-VIVO | cannabinoid system | EXPRESSION | microglial activation | Neuroprotective Agents - therapeutic use | Brain Edema - metabolism | Microglia - drug effects | Minocycline - pharmacology | Axons - drug effects | Motor Activity - drug effects | Male | Brain Injuries - metabolism | Receptor, Cannabinoid, CB2 - antagonists & inhibitors | Brain - drug effects | Receptor, Cannabinoid, CB1 - metabolism | Receptor, Cannabinoid, CB2 - metabolism | Animals | Neuroprotective Agents - pharmacology | Piperidines - pharmacology | Axons - pathology | Cannabinoid Receptor Antagonists - pharmacology | Indoles - pharmacology | Mice | Receptor, Cannabinoid, CB1 - antagonists & inhibitors | Brain Injuries - pathology | Pyrazoles - pharmacology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights